Ainos, Inc.

Listed Company

AIMDCIK 0001014763NasdaqNon-AcceleratedSmaller ReportingComputer Peripheral Equipment, NecTexasFY ends Dec 31

Period

FY 2025

Revenue

$124.2K

Net Income

$-14.77M

Total Assets

$20.87M

Equity

$7.56M

Shares Out

7.27M

Op. Cash Flow

$-4.61M

Business

Ainos, Inc. is a diversified healthcare company focused on developing point-of-care testing (POCT), very low-dose interferon therapeutics (VELDONA) and synthetic RNA-driven preventative medicine. It offers telehealth-friendly POCT devices powered by its AI Nose VOC sensing platform, VELDONA human therapeutics and VELDONA Pet supplements, plus related companion apps and SRNA research. Key business areas include VELDONA drug development, VOC POCT product lines (Ainos Flora, Ainos Pen, CHS430) and SRNA platform development. The company conducts operations and R&D in Taiwan, pursues regulatory approvals in the United States and Taiwan, and sells through outsourced manufacturers and global distribution partners.

Summary from filing dated 2025-03-07

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	124,157	20,729	122,112	4	594,563
Cost of revenues	−21,246	−52,595	−375,845	−2	−184,181
Gross profit (loss)	102,911	−31,866	−253,733	1	410,382
Research and development expenses (including amounts for related party of $947,084 and $1,418,887 for the years ended December 31, 2025 and 2024, respectively)	8	8	7	7	2
Selling, general and administrative expenses	6	5	6	9	2
Total operating expenses	14	14	13	15	4
Loss from operations	−14	−14	−13	−14	−4
Interest expense	−711,903	−616,467	−144,193	—	—
Issuance cost of senior secured convertible note measured at fair value	—	−308,336	—	—	—
Fair value change of senior secured convertible note	—	−275,624	94,207	0	—
Other income (expenses), net	−67,901	179,270	—	23,050	−2,547
Total non-operating expenses, net	−779,804	−1	−563,353	−30,478	−21,236
Net loss before income taxes	−15	−15	−14	−14	−21,236
Provision for income taxes	800	800	800	0	—
Net loss	−15	−15	−14	−14	−4
Net loss per common share - basic	−3.46	−7.82	−3.36	—	—
Net loss per common share - diluted	−3.46	−7.82	−3.36	—	—
Weighted-average shares used in computing net loss per common share-basic	4	2	4	—	—
Weighted-average shares used in computing net loss per common share-diluted	4	2	4	—	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	417,353	4	2	2	2
Accounts receivable	22	56	455	201,546	0
Inventory, net	295,565	143,756	167,593	595,222	0
Other current assets	425,859	301,077	419,521	195,787	466,198
Total current assets	1	4	2	3	2
Intangible assets, net	19	24	28	33	37
Property and equipment, net	343,281	559,645	876,572	1	1
Other assets	163,025	174,418	208,827	80,683	466,198
Total assets	21	29	32	37	41
Contract liabilities (including amounts to related party of $350,000 and nil as of December 31, 2025 and 2024, respectively)	350,000	106,329	112,555	—	—
Convertible notes payable (including amounts to related party of nil and $2,000,000 as of December 31, 2025 and 2024, respectively)	—	3	—	376,526	—
Accrued expenses and other current liabilities	728,683	848,615	1	1	—
Total current liabilities	1	4	1	2	31
Convertible notes payable - noncurrent (including amounts to related party of $11,000,000 and $9,000,000 as of December 31, 2025 and 2024, respectively)	11	9	3	0	—
Other long-term liabilities	1	348,945	135,829	8,096	—
Total liabilities	13	13	7	2	31
Commitments and contingencies	—	—	—	—	—
Preferred stock, $0.01 par value; 50,000,000 shares authorized as of December 31, 2025 and 2024, respectively; none issued and outstanding	—	—	—	0	0
Common stock, $0.01 par value; 300,000,000 shares authorized as of December 31, 2025 and 2024; 6,982,675 shares and 3,085,477 shares issued and 5,882,675 and 3,085,477 shares outstanding as of December 31, 2025 and 2024, respectively	69,827	30,854	46,778	40,023	96,251
Treasury stock, at cost (1,160,000 and nil shares held as of December 31, 2025 and 2024, respectively)	−2	—	—	—	—
Additional paid-in capital	77	69	63	59	20
Accumulated deficit	−68	−53	−38	−24	−10
Accumulated other comprehensive loss - translation adjustment	−249,291	−409,529	−270,473	−201,653	—
Total stockholders equity	8	16	24	35	10
Total liabilities and stockholders equity	21	29	32	37	41

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	5	5	5	5	2
Share-based compensation expense	2	4	1	—	160,978
Stock issued for special stock bonus	3	88,996	2	0	—
Issuance cost of senior secured convertible note measured at fair value	—	308,336	—	—	—
Issuance of common stock for consulting services	225,000	—	—	—	—
Changes in fair value of senior secured convertible note	—	275,624	−94,207	0	—
Gain on disposal of property, plant and equipment	−1,096	—	286,777	0	2,223
Accounts receivable	34	399	201,091	−201,546	0
Inventory	−151,809	23,837	221,767	−595,222	3,024
Other current assets	−123,085	118,444	−223,734	270,411	−415,054
Accrued expenses and other current and long-term liabilities	1	−105,559	−9,327	—	—
Net cash used in operating activities	−5	−6	−5	−3	−1
Purchase of property and equipment	−34,561	−21,331	−92,984	−633,823	−143,792
Decrease (Increase) in refundable deposits and other assets	32,338	−103,961	−8,541	—	—
Net cash used in investing activities	−2,223	−125,292	−101,525	−630,178	−180,517
Proceeds from convertible notes payable- noncurrent, related party	—	9	2	800,000	3
Proceeds from senior secured convertible notes payable	—	875,000	3	0	—
Proceeds from at-the-market offering, net of issuance costs	2	—	—	—	—
Repayment of convertible notes payable	−1	—	−390,000	—	—
Repayment of senior secured convertible notes payable	—	−1	—	—	—
Repayment of other notes payable, related party	—	−312,000	—	—	—
Payment of issuance cost of senior secured convertible note measured at fair value	—	−97,500	−114,026	0	—
Fractional shares paid out in cash for the reverse stock split	−260	—	—	—	—
Net cash provided by financing activities	1	8	5	4	3
Effect from foreign currency exchange	132,893	−84,896	−95,214	−78,021	5,375
Net (decrease) increase in cash and cash equivalents	−3	2	32,266	101,863	2
Cash paid for interest	32	21,671	16,897	43,254	19,380
Cash paid for income taxes	800	800	800	—	—
Issuance of common stock for consulting services	225,000	—	—	—	—
Conversion of senior secured convertible notes to common stock	—	2	254,237	0	—
Receivable from disposal of property, plant and equipment	1,697	—	—	—	—
Issuance of common stock for exchanging subsidiary company shares	2	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro